Stanford University
Showing 41-50 of 68 Results
-
Arutselvan Natarajan
Senior Research Scientist - Basic Life, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordSenior Scientist
-
Jun Hyung Park
Research and Development Science and Engineer 1, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordI joined in Cyclotron and radiochemstry facility in 2014. I focus on routine radiopharmaceutical production, including 18F tracers (18F-Flumazenil, 18F-FTC-146, 18F-FLT, 18F Arag, 18F-FSPG etc.); 11C tracers (11C UCB-J, 11C-raclopride, 11C-PIB, 11C-methionine, 11C DPA-713 etc.); 15O-H2O and 68Ga-DOTATATE radiochemistry for clinical use and supporting various of pre-clinical studies.
-
Shirin Pourashraf
Physical Science Research Scientist, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordStaff - Physical Science Research Scientist, Academic Staff at Rad/Molecular Imaging Program at Stanford
-
Jianghong Rao
Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry
Current Research and Scholarly InterestsProbe chemistry and nanotechnology for molecular imaging and diagnostics
-
Samantha Reyes
Postdoctoral Scholar, Molecular Imaging Program at Stanford
BioResearch Interests: Preclinical and clinical PET imaging, novel tracer validation in vivo, neuroinflammation, proteomics, theranostics and pharmacokinetic modeling
Samantha is an NIH T32 SMIS Postdoctoral Fellow who recently completed her PhD in Biomedical Physics in Dr. Michelle James' laboratory at Stanford, where her doctoral work focused on the development and translational validation of novel PET radiotracers for non-invasive imaging of neuroinflammation. She led the preclinical development and validation of two GPR84-targeted PET radiotracers for imaging innate immune activation in a murine model of multiple sclerosis, and also led the clinical data analysis for the first whole-body TSPO-PET/MRI study in female patients with ME/CFS. She is well-versed in preclinical and clinical PET quantitation, pharmacokinetic modeling, autoradiography, and cell-based assays. Her postdoctoral research applies her molecular imaging expertise to gynecological cancers, with a focus on using proteomics-driven biomarker discovery and novel theranostic radioligands to characterize the tumor microenvironment and improve response to therapy in women's cancer.
